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Toxoplasma gondii remains a serious cause of morbidity and mortality in individuals that are immunosup-
pressed, patients with AIDS in particular. The cellular immune response, especially by gamma interferon
(IFN-g)-producing CD81 T cells, is an essential component of protective immunity against the parasite. In the
present study the role of CD81 T cells during the reactivation of Toxoplasma infection in an immunocompro-
mised murine model was evaluated. Chronically infected mice were challenged with LP-BM5 virus, and the
kinetics of CD81 T-cell function was studied. At 10 weeks after viral infection, mice showed obvious signs of
systemic illness and began to die. At this stage, CD81 T cells were unresponsive to antigenic stimulation and
unable to kill Toxoplasma-infected targets. IFN-g production by the CD81 T cells from dual-infected animals
reached background levels, and a dramatic fall in the frequency of precursor cytotoxic T lymphocytes was
observed. Histopathological analysis of the tissues demonstrated signs of disseminated toxoplasmosis as a
result of reactivation of infection. However, treatment of the dual-infected animals with immune CD81 T cells
at 5 weeks post-LP-BM5 challenge prevented the reactivation of toxoplasmosis, and mice continued to live. Our
study for the first time demonstrates a therapeutic role for CD81 T cells against an opportunistic infection in
an immunocompromised state.
Toxoplasmosis is an opportunistic infection that induces a
strong cellular immune response in the normal host. Cell-
mediated immunity is essential for host resistance (31) against
this parasite. Infection in immunocompetent individuals re-
sults in asymptomatic chronic infection maintained by dormant
tissue cysts. In AIDS and other immunocompromised situa-
tions, the infection is reactivated, resulting in severe morbidity
and mortality in the infected host (11). Although Toxoplasma
spp. can infect all cells and organ systems, the predominant
manifestation of toxoplasma infection in patients with AIDS is
encephalitis (4). Toxoplasmic encephalitis in AIDS patients
results in multiple brain lesions, suggesting that reactivation of
infection is multifocal within the brain (21).
Loss of CD41 T cells from progressive human immunode-
ficiency virus (HIV) infection correlates with reactivation of T.
gondii infection in these patients (5). However, the underlying
mechanism that results in the activation of disease in these
immunocompromised subjects is not clear. Studies with mice
have shown that gamma interferon (IFN-g), a cytokine pro-
duced by both CD41 and CD81 T cells, is critical for protec-
tion during both acute and chronic infection (33, 34). Our
laboratory and others have shown that the CD81 T-cell pop-
ulation is more important for long-term survival of infection (6,
17, 35).
Infection of C57BL/6 mice with the LP-BM5 mixture of
helper and etiologic defective murine leukemia viruses
(MuLV) leads to the development of murine AIDS (MAIDS),
an inevitably fatal syndrome characterized by splenomegaly,
lymphadenopathy, hypergammaglobunemia, and a progressive
loss of B- and T-cell responses to antigens and mitogens (3,
26). Cytotoxic-T-lymphocyte (CTL) responses against alloan-
tigens were reduced at 8 to 9 weeks after viral infection (25).
The loss of T-cell responsiveness in vitro correlates with in-
creased susceptibility to a variety of infections (8, 14). While
MAIDS is not a perfect model of HIV infection, the patterns
of immunodeficiency induced in both syndromes are strikingly
similar. The similarities include early selective defects in CD41
T-cell function and impaired CD81 T-cell response late in the
course of the disease.
Previous studies by Gazzinelli et al. have shown that CD81
T cells are important for resistance to reactivation of toxoplas-
mosis in mice infected by LP-BM5 MuLV virus (10). Variation
in the susceptibility of mice to LP-BM5 infection has been
reported to be dependent in part on CD81 T cells (22). For
example, prior antibody depletion of CD81 T cells in resistant
A/J mice infected with LP-BM5 MuLV resulted in symptoms
similar to those seen in the susceptible C57BL/6 strain. In the
present study, we have analyzed the role of CD81 T cells
during the course of reactivation of T. gondii infection in mice
infected with LP-BM5 MuLV. The reactivation of disease co-
incided with the loss of CD81 function and could be prevented
by adoptive immunotherapy with CD81 T cells from toxoplas-
ma-vaccinated mice.
MATERIALS AND METHODS
Mice. Female C57BL/6 mice, 5 to 6 weeks old, obtained from Jackson Labo-
ratory at Bar Harbor, Maine, were used for the study.
Infection with virus. LP-BM5 MuLV (MAIDS) virus was prepared as previ-
ously described (19). G6 cells, originally provided to one of us by Janet Hartley
and Herbert Morse as a cloned cell line from SC-1 cells infected with LP-BM5
virus mixture were cocultured with uninfected SC-1 cells. Mice were infected
intraperitoneally with 100 ml of a virus stock that was quantitated by an XC
plaque assay (29) to contain approximately 7 3 105 ecotropic PFU/ml.
Parasites and antigen preparation. Chronic infection was established by 15
orally administered cysts of Me49 strain of T. gondii. Two weeks after feeding
cysts, infection was confirmed by determining the toxoplasma serum antibody
titer. Infected animals were challenged with LP-BM5 virus as described above.
Toxoplasma lysate antigen (TLA) was prepared from tachyzoites of the PLK
strain of T. gondii. The parasites were cultured in human fibroblasts and released
by forced extrusion through a 27-gauge needle. Parasites were isolated from host
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cell debris by separation by using a Percoll gradient. Purified parasites were
essentially free of any fibroblast contamination. The parasites were pulse soni-
cated eight times (18,000 Hz) at 10-s intervals at 4°C. The sonicate was centri-
fuged at 10,000 3 g for 15 min to remove nonsoluble antigen, and the protein
concentration was determined by a commercial assay (Bio-Rad Laboratories,
Cambridge, Mass.). The antigen was aliquoted and stored at 220°C until further
use.
CD81 T-cell purification and proliferation. After the administration of gen-
eral anesthesia, the spleens were removed and homogenized in a petri dish and
contaminating erythrocytes were lysed in an erythrocyte lysis buffer (Sigma
Chemical Co., St. Louis, Mo.). After two to three washes in Hanks balanced salt
solution (Life Technologies Inc., Gaithersburg, Md.) with 3% fetal bovine serum
(HyClone Laboratories, Logan, Utah), the CD81 T cells were separated by
microbeads (Miltenyl Biotec, Auburn, Calif.). The separation procedure was
conducted as recommended by the manufacturer. The purity of separated cells
was .95% as determined by fluorescence-activated cell sorter (FACS) analysis.
The assay was performed by previously described standardized method (17).
Antigen-specific proliferation of purified CD81 T cells was determined by
thymidine incorporation assay. CD81 T cells were suspended in RPMI 1640
(Life Technologies) and cultured in 96-well flat-bottomed plates in a 200-ml
volume at a concentration of 2 3 105 cells/well. The cells were stimulated with
either 5 mg/ml of concanavalin A (ConA) or 15 mg of TLA per ml in the presence
of 105 irradiated feeder cells. The feeder cells were obtained from syngeneic mice
and were irradiated at 3,000 rads. After 72 h of incubation at 37°C in 5% CO2,
[3H]thymidine (0.5 mCi/well; Amersham, Arlington Heights, Ill.) was added to
the wells. Pulsed splenocytes were harvested on a glass filter by use of an
automated multiple sample harvester and dried, and incorporation of radioactive
thymidine was then determined by liquid scintillation according to a standard
protocol (17).
IFN-g assay. The IFN-g assay of purified CD81 T cells from infected animals
was performed at various time points after LP-BM5 MuLV infection. CD81 T
cells from the infected animals were isolated as described above and stimulated
in vitro with TLA and irradiated feeder cells in a 24-well plate. After 72 h of
incubation, the cultures were harvested. Supernatants were then collected, cen-
trifuged, and stored at 270°C till further use. The supernatants were assayed for
IFN-g production by cytokine enzyme-linked immunosorbent assay (ELISA)
(Genzyme, Cambridge, Mass.).
Bulk cytotoxic assay. A CTL assay was performed according to a standard
procedure in our laboratory (17). Briefly, mouse peritoneal macrophages were
obtained by lavage 2 days after intraperitoneal inoculation with 1 ml of thiogly-
colate. The macrophages were washed three times in phosphate-buffered saline
(PBS) and dispensed at a concentration of 3 3 104 cells/well in U-bottom tissue
culture plates in medium. Macrophages were incubated overnight, and the next
morning were labeled with 51Cr (0.5 mCi/well; New England Nuclear Research
Products, Boston, Mass.) for 3 h at 37°C. After several washes in PBS (or until
the supernatant contained ,500 cpm), the macrophages were infected with
freshly isolated cell culture-grown tachyzoites of the PLK strain at a concentra-
tion of 5 3 104 parasites/well and incubated overnight. The next morning,
spontaneous lysis caused by overnight parasite infection was measured, and wells
exhibiting .500 cpm in the supernatants were excluded form the experiment.
Macrophages were washed three times in PBS and incubated with purified CD81
T cells at various effector/target (E/T) ratios in a final volume of 200 ml of culture
medium. CD81 T cells from T. gondii or dual-infected animals were purified by
use of magnetic beads as described above, and the purity was determined by
FACS. After the addition of T cells, the microtiter plates were centrifuged at
200 3 g for 3 min and incubated at 37°C for 3 h. Supernatant samples of 100 ml
were removed and assayed for released counts per minute (cpm) by scintillation
counting. The percent lysis was calculated as follows: (mean cpm of test sam-
ple 2 mean cpm of spontaneous release)/(mean cpm of maximal release 2 mean
cpm of spontaneous release) 3 100.
pCTL assay. The cytolytic activity of the CD81 T cells was quantitated by
determining the precursor CTL (pCTL) frequency of the infected mice by using
the limiting dilution assays. CD81 T cells from the splenocytes of infected
animals were isolated by magnetic separation with a resulting purity of .95%, as
determined by FACS analysis. Purified cells were cultured, by limiting dilution,
in 96-well round-bottom plates. Cells were grown in RPMI medium containing
appropriate growth factors, including 15 U of recombinant interleukin-2 (R & D
Chemicals, Minneapolis, Minn.) per ml, TLA (15 mg/ml), and 105 feeder cells per
well. Dilution of cells was carried from 1,250, 2,500, 5,000, 10,000, to 20,000
cells/well. Wells containing only antigen and feeder cells, without effector cells,
served as controls. After 1 week, the cells were harvested and incubated with
51Cr-labeled parasite-infected and uninfected macrophages. Macrophages were
collected and labeled as described above. The pCTL frequency was calculated
according to a standard formula (39).
Adoptive transfer of CD81 T cells. Mice were infected orally with 10 to 15 T.
gondii cysts as described above. At 4 weeks after the infection the animals were
splenectomized, and spleen cells from immunized and nonimmune controls were
isolated and collected. CD81 T cells were separated and purified. A total of 107
CD81 T cells were adoptively transferred via intravenous route to Toxoplasma-
infected animals at 5 to 8 weeks postchallenge with LP-BM5 virus. The survival
of the animals treated with immune or nonimmune CD81 T cells was monitored.
Histopathology. Tissues (lung, spleen, liver, and brain) from the dual-infected
animals transferred with immune CD81 T cells were collected at 10 weeks after
LP-BM5 infection. The tissues were immediately fixed in buffered 10% formalin,
embedded, sectioned, and stained with hematoxylin and eosin for routine histo-
logical examination. Sections were examined and photographed on Kodak TMax
film with an Olympus Van OX photomicroscope.
Statistical analysis. Student’s t test was used to determine the differences in
the proliferation of CD81 T cells (27).
RESULTS
CD81 T cells from dual-infected animals show decreased
antigen-specific proliferation. A proliferation assay was per-
formed to study the kinetics of antigen-specific CD81 T-cell
response in the T. gondii-infected animals after LP-BM5
MuLV infection. As expected, CD81 T cells from the mice
infected with T. gondii alone showed a significant (P 5 0.005)
proliferation in response to stimulation with TLA compared to
control unstimulated cultures (Fig. 1A). On the contrary,
CD81 T cells from Toxoplasma-infected mice, which were
challenged 5 weeks earlier with LP-BM5 MuLV virus, exhib-
ited significantly reduced antigen-specific proliferative re-
sponse (P 5 0.001). Although CD81 T cells from the mice
carrying dual infection or LP-BM5 MuLV virus alone prolif-
erated in response to ConA, the level of stimulation was lower
than for the uninfected animals or those infected with T. gondii
alone. At 8 weeks after viral infection CD81 T cells from the
dual-infected mice continued to show significantly lower (P 5
0.001) proliferation in response to antigenic stimulation (Fig.
1B). At this time point the downregulation of mitogenic re-
sponse of CD81 T cells from virally infected animals was
further enhanced. After 10 weeks after viral infection, CD81 T
cells from dual-infected animals completely fail to respond to
antigenic stimulation (Fig. 1C). The ConA response of the cells
from both dual-infected animals and the mice treated with
virus alone at this time is completely absent.
Effect of LP-BM5 infection on the IFN-g production by
memory CD81 T cells. Cytokine production upon antigenic
restimulation is an important characteristic of memory T cells
(36). IFN-g is known to be critical for protection against both
acute and chronic toxoplasma infections (33). Immune CD81
T cells have been reported to produce IFN-g during T. gondii
infection (6, 18, 35). The effect of LP-BM5 virus on the IFN-g
production of immune CD81 T cell was evaluated. Purified
CD81 T cells from the T. gondii-infected mice challenged 5
weeks earlier with LP-BM5 virus produced almost threefold-
less IFN-g compared to the control animals infected with T.
gondii alone (Table 1). The IFN-g production of these cells was
further compromised at 10 weeks after viral infection, and
nearly background levels of cytokine were released. CD81 T
cells from nonviral controls continued to produce high cyto-
kine titers in response to antigenic stimulation at this time
point. IFN-g levels could not be detected in the wells contain-
ing feeder cells alone (data not shown).
CD81 T cells from dual-infected animals show reduced cy-
tolytic response against T. gondii-infected targets. One of the
important characteristics of CD81 T cells is their ability to
exhibit cytolytic response against antigen-specific target (1).
Induction of CD81 CTLs against T. gondii infection has been
demonstrated earlier (12, 16, 32). Secondary in vitro CTL
response was assessed to determine the effect of LP-BM5 virus
on CD81 T-cell function. At 5 weeks postinfection no differ-
ence in the cytolytic response between the CD81 T cells from
dual-infected animals and the mice infected with T. gondii
alone was observed. CD81 T cells from both of these animals
showed almost 40 to 45% lysis of infected targets at 40:1 E/T
ratio (Fig. 2A). At 10 weeks after LP-BM5 MuLV infection,
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CD81 T cells from dual-infected animals were unable to kill
the toxoplasma-infected targets. The percent lysis at all E/T
ratios were equal to the background levels (Fig. 2B). However,
CD81 T cells from mice infected with T. gondii alone contin-
ued to show 40% lysis of the infected targets at a 40:1 E/T
ratio.
LP-BM5 MuLV infection downregulates the pCTL fre-
quency of anti-CD81 T cells from T. gondii-infected mice. In
order to better ascertain the effect of LP-BM5 MuLV infection
on the CTL function of CD81 T cells, pCTL frequency anal-
yses were performed. At 7 weeks after T. gondii infection, the
pCTL frequency of the infected animals was 1/3,297 cells (Fig.
3, A1) compared to 1/9,982 cells (Fig. 3, A2) in the group of
animals challenged with LP-BM5 virus 5 weeks earlier. These
values are within the range of variability (7), suggesting that
early LP-BM5 MuLV infection does not significantly affect the
cytotoxic function of CD81 T cells. However, when the assay
was performed 10 weeks after viral infection, the pCTL fre-
quency of the dual-infected animals was severely diminished
(1/146,537 cells) (Fig. 3, B2) compared to mice infected with T.
gondii alone (1/2,240 cells) (Fig. 3, B1).
Adoptive transfer of immune CD81 T cells prevents reacti-
vation of toxoplasmosis in immunocompromised animals.
Treatment of naive animals with toxoplasma-immune CD81 T
cells results in almost complete protection against acute T.
gondii infection (15). The role of CD81 T cells during chronic
toxoplasmosis, however, is not well studied. Experiments were
performed to determine whether CD81 T cells from toxoplas-
ma-immunized animals can prevent the reactivation of infec-
tion in the LP-BM5 immunocompromised mice chronically
infected with T. gondii. Mice carrying dual infection were
treated with 107 purified immune CD81 T cells at 5 to 8 weeks
after LP-BM5 infection. None of the animals treated with
immune CD81 T cells 5 weeks after viral infection died for up
to 16 weeks after viral challenge (Fig. 4). These mice did not
develop any signs of sickness (ruffled fur, sluggishness, etc.). In
comparison, 75% of the control animals treated with naive
CD81 T cells were dead by this time. Treatment of the dual-
FIG. 1. Proliferation of CD81 T cells from T. gondii-infected mice after
LP-BM5 challenge. C57BL/6 mice chronically infected with T. gondii were chal-
lenged with LP-BM5 virus as described in Materials and Methods. Pooled
splenocytes (n 5 three per group) were collected from dual-infected animals at
5 (A), 8 (B), and 10 (C) weeks after LP-BM5 challenge. CD81 T cells were
purified by magnetic separation (.95% pure, as determined by FACS) and
cultured in 96-well plates at the concentration of 2 3 105 cells/well. The cultures
were stimulated with ConA or TLA in the presence of 105 irradiated feeder cells.
After 72 h, proliferation was measured by determining thymidine incorporation.
The data are representative of two separate experiments. Columns: _, UI; 1,
Toxo; h LP-BM5; n , LP-BM5 plus Toxo.
TABLE 1. IFN-g levels of CD81 T cells from T. gondii-infected mice challenged with LP-BM5 virusa
Group
IFN-g levels (pg/ml) at:
5 wks after LP-BM5 infection 10 wks after LP-BM5 infection
Uninfected T. gondii T. gondii plus LP-BM5 Uninfected T. gondii T. gondii plus LP-BM5
Unstimulated ND 20 6 5.8 32 6 6.4 ND 18.7 6 1.6 9 6 3.7
Stimulated 10 6 0.5 2,587 6 360 875 6 160 7.8 6 0.6 1,876 6 175 30 6 15.9
a CD81 T cells from T. gondii-infected animals carrying LP-BM5 virus were isolated at 5 or 10 weeks after viral challenge. A total of 106 purified CD81 T cells (.95%
pure) were cultured in 24-well plates in the presence of 15 mg of TLA per ml and 5 3 105 irradiated feeder cells. After 72 h of incubation, the cultures were collected,
centrifuged, and stored at 270°C. The supernatants were assayed for IFN-g by ELISA. ND, not detected.
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infected animals with immune CD41 T cells had no effect on
the mortality of these animals (data not shown). Immune
CD81 T cells failed to protect the dual-infected animals when
the transfer was performed 8 weeks after LP-BM5 infection
(data not shown). Like the mice treated with nonimmune
CD81 T cells, 70 to 80% of these animals succumbed to in-
fection by 12 weeks after LP-BM5 challenge.
To confirm that the observed mortality in these animals was
due to the reactivation of T. gondii infection, histopathological
analysis of the tissues was performed at 10 weeks after LP-
BM5 infection. This is the time point when complete loss of
CD81 T-cell function in the dual-infected animals was ob-
served. Sections of various organs of the mice treated with
naive CD81 T cells revealed extensive T. gondii replication and
necrosis. Areas of interstitial lymphocytic infiltration in the
lung contained patches of necrosis in which abundant Toxo-
plasma tachyzoites could be identified (Fig. 5A). Within these
areas of necrosis there were scattered lymphocytes, mononu-
clear cells, and polymorphonuclear granulocytes (PMN). The
follicular architecture of the spleen was effaced, with loss of the
normal organization replaced by a lymphocytic infiltrate in
which numerous large phagocytic cells with engulfed pycnotic
mononuclear cells were seen (Fig. 5D). Areas of necrosis and
acute inflammatory infiltrate were seen, including many intra-
cellular and extracellular T. gondii tachyzoites. Examination of
LP-BM5 MuLV-infected mice at 8, 10, and 12 weeks after
infection showed that the splenic effacement is seen in the
absence of infection with T. gondii (data not shown). There was
moderate fatty metamorphosis of the cytoplasm, with scattered
small nodules of necrosis throughout the liver parenchyma
(Fig. 5G). These nodules had few lymphocytes, scattered
PMNs, and abundant T. gondii tachyzoites. There were scat-
tered foci of necrosis in the white matter of the brain, with T.
gondii tachyzoites evident (Fig. 5J), and the meninges and
penetrating vessels had perivascular lymphocytic infiltrates.
Sections from mice at 5 weeks after transfer of immune
CD81 T cells showed intense lymphocytic and mononuclear
cell infiltrates in the lung with scattered plasma cells and
PMNs, but there was no evidence of necrosis or T. gondii
replication (Fig. 5B). Follicular architecture was preserved in
the spleen, with scattered large phagocytes similar to those
seen in the control mice receiving naive CD81 T cells (Fig.
5E). Replicating T. gondii organisms were not evident. Hepa-
tocytes had finely granular cytoplasm, and there were scattered
small nodules of lymphocytic inflammatory cells throughout
the parenchyma of the liver (Fig. 5H). The brain contained
FIG. 2. LP-BM5 infection downregulates the cytolytic response of immune
CD81 T cells. Splenocytes from saline injected, toxoplasma infected and dual
infected animals (n 5 three/gp) were isolated and pooled at 5 (A) and 10 (B)
weeks after LP-BM5 challenge. The cells were cultured in vitro with TLA
(toxoplasma lysate antigen; 15 mg/ml). After 5 days of incubation viable cells
were separated on Ficoll and CD81 T cells were isolated by magnetic separation.
Purified CD81 T cells were cultured with 51Cr-labeled macrophages infected
with the PLK strains of T. gondii or uninfected targets at various E/T ratios. At
4 h after incubation the cytolytic activity was determined by measuring radioiso-
tope release in the culture supernatant. The experiment was performed twice
with similar findings each time. The data presented are representative of one
experiment. Infected targets: F, saline; n , Toxo; , Toxo plus LP-BM5. Unin-
fected targets: E, saline; h, Toxo; , Toxo plus LP-BM5.
FIG. 3. LP-BM5 infection reduces the pCTL frequency in the T. gondii-infected animals. CD81 T cells from the pooled splenocytes (n 5 three/group) from
dual-infected animals were separated at 5 (A) or 10 (B) weeks after LP-BM5 challenge. Purified CD81 T cells (.95% pure) were cultured by limiting dilution in the
presence of antigen and irradiated feeder cells. After 1 week in culture, the pCTL frequency of CD81 T cells was determined. The experiment was performed twice.
The data presented are representative of one experiment.
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rare foci of necrosis and inflammation, with T. gondii
tachyzoites and evidence of cyst formation (Fig. 5K and L).
The meninges and penetrating vessels showed evidence of lym-
phocytic infiltration. On the contrary, mice treated with im-
mune CD81 T cells 8 weeks after LP-BM5 challenge showed
extensive necrosis and T. gondii replication in the lung, spleen,
and liver (Fig. 5C, F, and I), as well as in mesenteric fat and
brain (data not shown), results similar to those seen in animals
treated with naive CD81 T cells.
DISCUSSION
Toxoplasmosis is a major problem in immunocompromised
individuals, in particular in individuals with AIDS. Earlier
studies by Lang et al. have shown that among the nonviral
opportunistic infections, encephalitis due to T. gondii was the
most frequent cause of mortality in the HIV-infected popula-
tion (20). In a majority of these cases toxoplasmic encephalitis
was due to recrudescence of chronic infection as a result of loss
of cellular immune responses. We used a mouse model for
retrovirus-induced immunodeficiency to study the reactivation
of chronic T. gondii infection. Our findings suggest that reac-
tivation of toxoplasmosis in the immunocompromised mice
coincides with the loss of CD81 T-cell function. The reactiva-
tion of the disease could be prevented if these animals are
treated with immune CD81 T cells from immunocompetent
mice. These studies clearly demonstrate that immune CD81 T
cells are critical for the prevention of reactivation in mice
chronically infected with T. gondii. A protective effect of adop-
tively transferred immune CD81 T cells has been previously
reported (15). However, the present findings for the first time
demonstrate the role of these cells in preventing the reactiva-
tion of toxoplasma infection in an immunocompromised host.
One of the major complications of HIV infection is the
progressive loss of CD41 T cells (5). Both CD41 and CD81 T
cells are known to play a role in resistance to T. gondii infection
(9). However, immunity during chronic infection has been re-
ported to be largely dependent on CD81 T cells, with IFN-g
playing a central role in the protection (6, 35). Like HIV
infection in humans, mice with MAIDS have been reported to
exhibit a loss of CD41 T-cell function with the passage of time
(25, 28). This ultimately results in defective CD81 T-cell re-
sponse in these animals. Thus, the mechanism of reactivation
of T. gondii infection in the dual-infected animals is due to lack
of CD41 T-cell help to the effector CD81 T-cell population.
Previous studies have shown that resistance to lethal reactiva-
tion of toxoplasmosis in animals with MAIDS is dependent on
CD81 T cells and IFN-g (10). These findings are strengthened
by the reports that reactivation of toxoplasmosis during HIV
infection occurs in individuals with full-blown AIDS, when
CD81 T-cell immunity is compromised (30).
In the present study, CD81 T cells start to show a loss of
toxoplasma-specific proliferation starting at 5 weeks after
MAIDS infection. By 10 weeks after viral challenge, the im-
mune CD81 T cells completely failed to respond to antigenic
or mitogenic stimulation. The cells were unable to lyse infected
targets, and IFN-g production in response to antigenic stimu-
lation was barely detectable. Animals at this time point look
very sick and started to die as a result of the reactivation of
toxoplasma infection. However, if the dual-infected animals
were treated with immune CD81 T cells at 5 weeks after
infection, the reactivation of toxoplasmosis was prevented and
there was no dissemination of infection. These animals showed
no sign of sickness and continued to live for up to at least 16
weeks after viral challenge. Histopathological analysis of the
tissues of these animals at 10 weeks after onset of MAIDS
showed no evidence of reactivation of chronic toxoplasmosis. If
the transfer was delayed to 8 weeks after LP-BM5 MuLV
infection, the reactivation of toxoplasmosis could not be pre-
vented. Evidence of disseminated infection similar to the con-
trol animals treated with naive CD81 T cells was revealed
upon histopathological examination of the tissues. The intra-
cellular multiplication of T. gondii and necrosis of tissues was
superimposed on the lymphoid infiltrates, a finding typical of
LP-BM5 MuLV infection (38). Infection with LP-BM5 MuLV
alone produces an appearance in the spleen similar to that
seen in dual-infected mice, without the evidence of increased
phagocytosis.
The inability of immune CD81 T cells to protect the immu-
nocompromised animals at 8 weeks after onset of MAIDS may
be due to the fact that the toxoplasma infection by this time has
completely reactivated and the parasites have disseminated to
various tissues. Immune CD81 T cells are thus ineffective in
controlling overwhelming toxoplasma infection. This view is
supported by the observations of Gazzinelli et al., who re-
ported significantly decreased cyst numbers in the brains of
dual-infected animals beginning 8 weeks after viral infection
(10).
Although endogenous CD81 T cells from the dual-infected
animals are not severely compromised at 5 weeks after viral
infection, these cells are unable to prevent the reactivation of
toxoplasma infection in the host. This finding can be attributed
to the reduced ability of these cells to proliferate and produce
IFN-g in response to T. gondii stimulation. In contrast, im-
mune CD81 T cells from the mice infected with T. gondii alone
exhibit significantly higher proliferation and IFN-g production
when stimulated with toxoplasma antigen. When transferred to
the immunocompromised host the immune CD81 T cells pre-
vent the reactivation of infection in immunocompromised an-
imals, which results in their survival. The possibility that, like
the endogenous CD81 T-cell population, the donor CD81 T
cells ultimately may undergo immunosuppression cannot be
ruled out. However, based on our current observations, these
FIG. 4. Adoptive transfer of immune CD81 T cells prevents the reactivation
of T. gondii infection in the LP-BM5-infected host. C57BL/6 mice infected with
T. gondii were challenged with LP-BM5 virus as described above. Dual-infected
animals were injected intravenously with 107 immune CD81 T cells at 5 weeks
after LP-BM5 infection. The animals were monitored daily for morbidity or
mortality. There were 8 animals per group, and the experiment was performed
twice with similar findings. The data presented are representative of one exper-
iment. Symbols: }, naive CD8; n , immune CD8.
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FIG. 5. Microphotographs of sections of lung (A to C), spleen (D to F), liver (G to I), and brain (J to L) of T. gondii-infected animals challenged with LP-BM5
virus. Magnifications: A to C, 3170; D, 385; E, 342.5; F, 385; G to I, 3170; J and K, 385; L, 3170. (A) Lung of LP-BM5 and toxoplasma-infected mouse with
adoptively transferred naive CD81 T cells at 5 weeks after LP-BM5 infection showing necrosis of the lung parenchyma with identifiable tachyzoites. (B) Lung of
dual-infected mouse with adoptively transferred immune CD81 T cells at 5 weeks after LP-BM5 challenge showing lymphocytic infiltration of the interstitial space (no
tachyzoites can be identified). (C) Lung of dual-infected mouse with adoptively transferred immune CD81 T cells at 8 weeks after LP-BM5 infection showing extensive
necrosis of lung tissue with rare tachyzoites. (D) Spleen of dual-infected mouse with adoptively transferred naive CD81 T cells showing effacement of follicular
architecture and necrosis. (E) Spleen of dual-infected mouse with adoptively transferred immune CD81 T cells showing preservation of follicular architecture. (F)
Spleen of dual-infected mouse with adoptively transferred immune CD81 cells at 8 weeks after LP-BM5 infection showing necrosis and effacement of follicular
architecture. (G) Liver of dual-infected mouse with adoptively transferred naive CD81 T cells showing extensive tachyzoite replication and necrosis. (H) Liver of
dual-infected mouse with adoptively transferred immune CD81 T cells at 5 weeks showing lymphocytic infiltrate within the parenchyma but no identifiable tachyzoites.
(I) Liver of dual-infected mouse with adoptively transferred immune CD81 cells at 8 weeks showing extensive necrosis and tachyzoite multiplication. (J) Brain of
dual-infected mouse with adoptively transferred naı¨ve CD81 T cells at 5 weeks showing a microscopic focus of inflammation and necrosis and perivascular lymphocytic
infiltrates. (K) Brain of dual-infected mouse with adoptively transferred immune CD81 T cells at 5 weeks showing extensive perivascular lymphocytic infiltration but
no necrosis. (L) Brain of dual-infected mouse with adoptively transferred immune CD81 T cells at 5 weeks showing cyst without surrounding cellular reaction.
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cells definitely play a protective role in the initial stages of
reactivation of T. gondii infection.
Studies with LP-BM5 infection have shown that the infected
animals show early loss of CD41 T-cell effector functions,
including help for the CD81 T-cell response (26). The CD41
help has been reported to be critical for certain infectious
disease and tumor models, where protective immunity is de-
pendent on CD81 T cells (23, 24, 37), as is the case with T.
gondii infection, where CD81 T-cell immunity is required for
resistance against the parasite (2, 15, 33). CD81 T cells and
IFN-g keep the infection under check by restricting it to a
chronic or dormant state. However, a lack of adequate CD41
T-cell help, probably as a result of LP-BM5 infection, is fol-
lowed by a poor CD81 T-cell response against the parasite.
This results in the absence of sufficient host immune surveil-
lance required for preventing the reactivation of infection.
Treatment with CD81 T cells from an immunocompetent host
can make up for this loss, and the infection can be controlled.
Adoptive immunotherapy with activated CD81 T cells has
been suggested as a therapy for HIV infection (13, 40). In one
of these studies the transfer of activated CD81 T cells to AIDS
patients resulted in stable CD41 and CD81 T-cell counts,
lower levels of antigenemia, and minimal toxicity over the
period of study (40). The treated individuals improved clini-
cally and remained stable. The ability of adoptively transferred
CD81 T cells to protect naive mice against acute toxoplasma
infection has been demonstrated (15). The role of immune
CD81 T cells in the reactivation model of T. gondii infection
has not been thoroughly studied. Our studies for the first time
demonstrate that immunotherapy with immune CD81 T cells
can prevent reactivation of toxoplasmosis in a retrovirus-in-
duced immunocompromised state.
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